Merck Wins FOSAMAX® (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture Claims
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today said a
jury found in its favor in the Glynn v. Merck case in the U.S.
District Court for the District of New Jersey. In the case, the
plaintiff claimed she used FOSAMAX and subsequently suffered an atypical
femur fracture.
Language:
English
Contact HTML:
MerckMedia Contact:Lainie Keller, 908-423-4187orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Source Type: news